Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
life sciences
national blog main
clinical trials
national
europe top stories
fda
national top stories
san francisco top stories
boston blog main
boston top stories
europe blog main
new york top stories
san francisco blog main
artificial intelligence
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abaloparatide
abbvie
alkermes
allergan
amgen
amy heimberer
arena pharmaceuticals
What
drug
9
×
medicine
9
×
fda
patients
cancer
discovery
european
genomic
marketing
million
raises
weight
admissions
adverse
alex
alkermes
alzheimer's
amgen
amgen’s
announced
antipsychotic
approval
approved
atrophy
bad
benefits
biologic
bottleneck
brain
called
carries
case
caveats
ceo
clinical
collaboration
commonly
considered
daily
data
Language
unset
Current search:
medicine
×
biotech
×
drug
×
@tech.eu
2 years ago
Medication intelligence platform Synapse Medicine raises €25 million
@techcrunch.com
2 years ago
Federated Genomic data startup Lifebit raises $60M round led by Tiger Global
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority